摘要
目的探讨自体肿瘤组织致敏的树突状细胞瘤苗治疗肝癌的可行性和安全性。方法培养12例肝细胞癌患者外周血单核细胞来源的树突状细胞，以自体肿瘤组织裂解物致敏并诱导成熟制备成树突状细胞瘤苗用于肝癌患者的治疗并进行临床观察。12例患者共进行了41次瘤苗治疗。结果90ml外周血诱导出树突状细胞的数量为1．69×10^7（1，69×10^7±9，44×10^6），63．41％（26／41）人次瘤苗注射后出现迟发性超敏反应，未发生严重的不良反应。平均随访9个月，在已有肝癌复发转移的4例患者中，1例稳定时间已达17个月，3例肝癌仍有进展，8例行肝癌根治切除术后应用瘤苗进行治疗的患者6例无复发转移征象，2例在治疗期间发现肝内复发进展。结论自体肿瘤组织致敏的树突状细胞瘤苗可激发肝癌患者的免疫反应。安全可行，无不良反应，可应用于肝癌患者的临床治疗。
Objective To investigate the feasibility and safety of autologous tumor tissue lysate loading dendritic cells（DC） for the treatment of hepatocellular carcinoma （HCC）. Methods The monocytes-derived DC were induced and antigen loaded with tumor tissue lysate to produce DC vaccine. Vaccination and clinical observation were conducted in 12 HCC patients for 41 times, Results The average output of DC was 1.69 × 10^7 （ 1.69 × 10^7 ±9.44 × 10^6 ） from 90 ml peripheral blood. 63.41% （ 26/41 ） patients appeared to develop delayed-type hypersensitivity after intradermal injection. After an average of 9 months follow up, 1 patient out of 4 recurrence and metastasis patients survived for 17 months. The other three patients progressed. Out of 8 patients undergoing immunotherapy postoperatively ,6 patients had no signs of recurrence and the others were found to have liver recurrence and progression. Conclusion DC based immunotherapy is safe and feasible,with no side effects,which can be applied in the immunotherapy strategy of HCC patients.
出处
《中国综合临床》
北大核心
2008年第7期693-696,共4页
Clinical Medicine of China
关键词
肝癌
树突状细胞
免疫治疗
Hepatocellular carcinoma
Dendritic Cell
Immunotherapy
